# Newleos Therapeutics

**Canonical:** https://apis.io/providers/newleos-therapeutics/  
**Website:** https://newleos.com/  
**APIs profiled:** 0

Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned CNS drug-development leaders, headquartered in Boston, Massachusetts. Its pipeline, licensed from Roche, develops oral small-molecule therapeutics targeting GABAA-gamma1, V1a, TAAR1 and GABAA-alpha5 mechanisms, with first- or best-in-class potential for general anxiety, social anxiety, substance use disorders, and cognitive impairment. Newleos is a pharmaceutical R&D company with no public developer or API product surface; this profile captures its corporate web presence for the API Evangelist network.

## Kin Score — 6.7 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 6.7).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 1.2 |
| Commercial Clarity | 15.8 |
| Access Clarity | 15.8 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Pharmaceuticals, Mental Health, Neuroscience, Clinical Trials, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/newleos-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.